team size
5 - 9
funding probability score
total disclosed funding
last round valuation estimate
disclosed funding rounds
latest round
latest funding stage
next round estimate
development stage
number of investors
number of competitors
monthly web visits
twitter followers
HQ address
Herrmann-von-Helmholtz-Platz 1 Eggenstein, Leopoldshafen, 76344, DEU
amcure, a spin-off from the Karlsruhe Institute of Technology, develops AM001 as first-in-class compound. AM001’s mode of action differs fundamentally from known experimental or approved compounds for the inhibition of angiogenesis and metastasis in cancer therapy, which in most cases either address only a single RTK or target multiple RTKs as broadband inhibitors. By its novel targeting strategy AM001 combines the advantages of receptor specificity and broadband inhibition. Application area for AM001 will be highly metastasizing cancer types with a focus on pancreatic cancer.

There is much more to this profile.
Log in or sign up for free to see the whole thing.

Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats